1. Glasgow prognostic score can be a prognostic indicator after percutaneous coronary intervention: a two-center study in Japan
- Author
-
Ryota Noike, Shunsuke Matsuno, Hideo Amano, Takayuki Otsuka, Hiroto Kano, Junji Yajima, Hiroaki Semba, Shingo Matsumoto, Rine Nakanishi, Minoru Matsuhama, Takanori Ikeda, Ryo Okubo, Naoharu Yagi, Hiroto Aikawa, Yuji Oikawa, Yuko Kato, Takayuki Yabe, Takuto Arita, Mikio Kishi, Shinya Suzuki, Mitsuru Iida, Takeshi Yamashita, Shojiro Hirano, Yoshimasa Kojima, Tokuhisa Uejima, and Yosuke Oka
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Gastroenterology ,chemistry.chemical_compound ,Percutaneous Coronary Intervention ,Japan ,Internal medicine ,medicine ,Humans ,Myocardial infarction ,Renal Insufficiency, Chronic ,Retrospective Studies ,Heart Failure ,Creatinine ,business.industry ,Percutaneous coronary intervention ,Prognosis ,medicine.disease ,Brain natriuretic peptide ,chemistry ,Heart failure ,Conventional PCI ,Hemodialysis ,Cardiology and Cardiovascular Medicine ,business ,Kidney disease - Abstract
Glasgow prognostic score (GPS) has been used to evaluate inflammatory response and nutritional status. This study aimed to investigate the impact of nutritional status on cardiac prognosis by using GPS in patients after undergoing percutaneous coronary intervention (PCI). We included 862 patients who underwent PCI for stable angina pectoris between 2015 and 2018. We used the original cutoff values, which were an albumin (Alb) level of 3.5 g/dl and a C-reactive protein (CRP) level of 0.3 mg/dl. We categorized them into the three groups: originally defined GPS (od-GPS) 0 (high Alb and low CRP), 1 (low Alb or high CRP), and 2 (low Alb and high CRP). Major adverse clinical events (MACEs) included all-cause death, nonfatal myocardial infarction, revascularization, and hospitalization for heart failure. The median follow-up period was 398.5 days. During the follow-up, MACEs occurred in 136 patients. Od-GPS 2 had higher prevalence rates in terms of chronic kidney disease (CKD; 31.7% [229/722] vs. 44.9% [53/118] vs. 63.6% [14/22], p
- Published
- 2021